Gene expression meta-analysis identifies chromosomal regions involved in ovarian cancer survival

Genes Chromosomes and Cancer

Volumn 48, Issue 8, 2009, Pages 711-724

  Thomassen, Mads ^a,b   Jochumsen, Kirsten M ^a   Mogensen, Ole ^a   Tan, Qihua ^a,b   Kruse, Torben A ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; THROMBOPOIETIN;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 11P; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 6P; CHROMOSOME 7; CHROMOSOME 7P; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME BAND; DEATH; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; KARYOTYPE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; UPREGULATION; VALIDATION PROCESS;

CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN; DATABASES, GENETIC; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; KARYOTYPING; MUTATION; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 67650444380     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20676     Document Type: Article

References (41)

1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. 2006. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77-85.
2. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF. 2005. High-resolution mapping of genomic imbalance and identification of gene expression pro-files associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7:603-613.
3. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, Dressman HK, West M, Nevins JR. 2006. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
4. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. 2007. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25:2281-2287.
5. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A. 2008. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 49:451-461.
6. Byrom J, Mudaliar V, Redman CW, Jones P, Strange RC, Hoban PR. 2004. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors. Int J Oncol 24:1271-1277.
7. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, bu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. 2006. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559-564.
8. Eccles DM, Gruber L, Stewart M, Steel CM, Leonard RC. 1992. Allele loss on chromosome 11p is associated with poor survival in ovarian cancer. Dis Markers 10:95-99.
9. Fischer TC, Gellrich S, Muche JM, Sherev T, Audring H, Neitzel H, Walden P, Sterry W, Tonnies H. 2004. Genomic aberrations and survival in cutaneous T cell lymphomas. J Invest Dermatol 122:579-586.
10. Gabra H, Taylor L, Cohen BB, Lessels A, Eccles DM, Leonard RC, Smyth JF, Steel CM. 1995. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 72:367-375.
11. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. 1998. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 58:2166-2169.
12. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. 2005. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11:2149-2155.
13. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. 2006. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66:1354-1362.
14. Homsi J, Daud AI. 2007. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14:285-294.
15. Jochumsen J, Tan Q, Høgdall E, Høgdall C, Kjær S, Blaakær J, Kruse T, Mogensen O. Gene expression profiles as a prognostic marker in woman with ovarian cancer. Int J Gynecol Cancer (in press).
16. Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de HW, de Krijger RR, Verhofstad AA, Hermus AR, Kummer JA, Skogseid B, Volante M, Voogd AC, Ramaekers FC, Speel EJ. 2007. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocr Relat Cancer 14:769-779.
17. Juneja S, Matthews J, Lukeis R, Laidlaw C, Cooper I, Wolf M, Ironside P, Garson OM. 1997. Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin's lymphoma. Leuk Lymphoma 25:493-501.
18. Kohlberger PD, Kieback DG, Mian C, Wiener H, Kainz C, Gitsch G, Breitenecker G. 1997. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: Correlation with p53 protein overexpression and Ki-67. J Soc Gynecol Investig 4:262-264.
19. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. 2006. Plasma thrombopoietin compared with immunoglobulin heavychain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 108:1001-1006.
20. Lafky JM, Wilken JA, Baron AT, Maihle NJ. 2008. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232-265.
21. Lambros MB, Fiegler H, Jones A, Gorman P, Roylance RR, Carter NP, Tomlinson IP. 2005. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol 205:29-40.
22. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R. 2006. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 84:671-681.
23. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68.
24. Lo HW, Hung MC. 2006. Nuclear EGFR signalling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94:184-188.
25. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Pellin A, Lopez-Guerrero JA, Callaghan R, Benito R, Roldan P, Piquer J, Llacer J, Barbera J. 2005. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin Neuropathol 24:209-218.
26. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. 2007. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67:3074-3084.
27. Osterberg L, Levan K, Partheen K, Helou K, Horvath G. 2005. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet 163:144-150.
28. Partheen K, Levan K, Osterberg L, Helou K, Horvath G. 2004. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer 40:342-348.
29. Pejovic T, Iosif CS, Mitelman F, Heim S. 1996. Karyotypic characteristics of borderline malignant tumors of the ovary: Trisomy 12, trisomy 7, and r(1) as nonrandom features. Cancer Genet Cytogenet 92:95-98.
30. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I, Garcia-Conde J, Dyer MJ, Terol MJ, Pinkel D, Martinez-Climent JA. 2005. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105: 4445-4454.
31. Santos GC, Zielenska M, Prasad M, Squire JA. 2007. Chromosome 6p amplification and cancer progression. J Clin Pathol 60:1-7.
32. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. 2004. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700-4710.
33. Staebler A, Karberg B, Behm J, Kuhlmann P, Neubert U, Schmidt H, Korsching E, Burger H, Lelle R, Kiesel L, Bocker W, Shih I, Buchweitz O. 2006. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 45:905-917.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression pro-files. Proc Natl Acad Sci USA 102:15545-15550.
35. Suehiro Y, Umayahara K, Ogata H, Numa F, Yamashita Y, Oga A, Morioka H, Ito T, Kato H, Sasaki K. 2000. Genetic aberrations detected by comparative genomic hybridization predict outcome in patients with endometrioid carcinoma. Genes Chromosomes Cancer 29:75-82.
36. Suzuki S, Moore DH, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. 2000. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60:5382-5385.
37. Tao Y, Pinzi V, Bourhis J, Deutsch E. 2007. Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway-Therapeutic perspectives in cancer. Nat Clin Pract Oncol 4:591-602.
38. Thomassen M, Tan Q, Kruse TA. 2009. Gene expression metaanalysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat 113:251-252.
39. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD. 2008. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198-5208.
40. Wennmalm K, Calza S, Ploner A, Hall P, Bjohle J, Klaar S, Smeds J, Pawitan Y, Bergh J. 2007. Gene expression in 16q is associated with survival and differs between Sorlie breast cancer subtypes. Genes Chromosomes Cancer 46:87-97.
41. Wessels PH, Twijnstra A, Kessels AG, Krijne-Kubat B, Theunissen PH, Ummelen MI, Ramaekers FC, Hopman AH. 2002. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 33:279-284.